A diabetes-turned-weight-loss medication could potentially have multiple benefits, including improving cardiovascular health. Initially approved as a diabetes drug, semaglutide mimics the gut hormone GLP-1, which is responsible for making us feel full after eating. By providing an additional dose of this hormone, semaglutide can lead to significant weight loss. Recent clinical trial results released by Novo Nordisk, the drug’s manufacturer, on August 8, suggest that weekly injections of semaglutide in overweight or obese adults can reduce the risk of serious heart or blood vessel problems by 20 percent, even in individuals without diabetes. This is a significant finding as it is the first time a weight loss drug has demonstrated benefits beyond weight loss itself.
2023-08-29 08:00:00
Post from www.sciencenews.org